Date: 28-Aug-2019

U.S. FDA gives fast track status to AstraZenecas diabetes drug Farxiga

Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease (CKD). Farxiga, one of AstraZenecas top 10 drugs by sales, is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine.